Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

NCT04598893 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL: Teplizumab
OTHER: Placebo

Sponsor

Provention Bio, a Sanofi Company